The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.
More Latest News
August 29, 2019
Under a State of Emergency, a pharmacist, in his or her professional judgment, may be able to refill prescriptions early. Continue reading
August 23, 2019
The Quarterly Performance Report for the fourth quarter of the 2018-2019 fiscal year is now available online. Continue reading